Date published: 2025-10-10

021-6093-6350

SCBT Portrait Logo
Seach Input

ALG11 抑制因子

ALG11 inhibitors belong to a distinct chemical class of compounds that play a crucial role in the field of glycobiology, specifically in the realm of protein glycosylation. Glycosylation is a fundamental post-translational modification process in which complex sugar molecules, or glycans, are attached to proteins, thereby influencing their structure, stability, and function. ALG11 inhibitors are a group of chemical compounds designed to target and disrupt the function of ALG11, a key enzyme involved in the early stages of N-linked glycosylation, a specific type of glycosylation that occurs in the endoplasmic reticulum of eukaryotic cells.

ALG11, short for Asparagine-linked glycosylation 11, is an enzyme that catalyzes the transfer of a specific glycan precursor onto nascent proteins during N-linked glycosylation. This enzymatic step is essential for the proper folding and functioning of glycoproteins, which are involved in various cellular processes, including cell-cell communication, signal transduction, and immune response. ALG11 inhibitors work by interfering with the activity of this enzyme, leading to the accumulation of under-glycosylated or misfolded proteins in the endoplasmic reticulum. This disruption can have a profound impact on cellular homeostasis and has implications in various biological contexts, such as protein quality control and cellular stress responses.

関連項目

产品名称CAS #产品编号数量价格应用排名

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
¥2008.00
¥7311.00
¥18694.00
3
(0)

伦伐替尼通过与ALK1的ATP结合位点结合来抑制ALK1,阻止SMAD1/5等下游信号蛋白的磷酸化,从而抑制血管生成和肿瘤生长。

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
¥632.00
¥2933.00
¥4693.00
129
(3)

索拉非尼通过靶向多种激酶(包括 ALK1、Raf-1 和 VEGFR-2)抑制 ALK1 信号传导,从而减少血管生成和肿瘤生长。

Sunitinib Malate

341031-54-7sc-220177
sc-220177A
sc-220177B
10 mg
100 mg
3 g
¥2177.00
¥5754.00
¥12094.00
4
(1)

舒尼替尼可抑制 ALK1 和其他激酶,阻止 SMAD1/5 等下游靶点的磷酸化,抑制血管生成和肿瘤进展。

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
¥1038.00
¥2302.00
1
(1)

卡博替尼以 ALK1、VEGFR-2 和 MET 为靶点,通过抑制 ALK1 磷酸化和下游信号通路,减少血管生成和肿瘤生长。

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
¥3610.00
¥4851.00
3
(0)

瑞戈非尼是一种多激酶抑制剂,以 ALK1、VEGFR-2 等为靶点,通过阻断 ALK1 介导的信号传导来破坏血管生成和肿瘤生长。

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
¥1433.00
¥2008.00
2
(1)

帕唑帕尼(Pazopanib)可抑制 ALK1 和 VEGFR-2,通过破坏 ALK1 依赖性信号通路,减少血管生成和肿瘤生长。

BIBF1120

656247-17-5sc-364433
sc-364433A
5 mg
10 mg
¥2031.00
¥3554.00
2
(0)

Nintedanib 可抑制 ALK1、血管内皮生长因子受体(VEGFR)和表皮生长因子受体(PDGFR),通过干扰 ALK1 介导的信号转导抑制血管生成并抑制肿瘤生长。

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
¥1941.00
¥10876.00
2
(1)

泊纳替尼是一种多激酶抑制剂,靶向 ALK1 和其他激酶,通过阻断 ALK1 磷酸化和下游通路抑制血管生成和肿瘤生长。

Vandetanib

443913-73-3sc-220364
sc-220364A
5 mg
50 mg
¥1884.00
¥15265.00
(1)

Vandetanib 可抑制 ALK1 和 VEGFR-2,通过干扰 ALK1 介导的信号转导破坏血管生成并抑制肿瘤进展。

Tivozanib

475108-18-0sc-475339
5 mg
¥3610.00
(0)

Tivozanib 是一种血管内皮生长因子受体抑制剂,可通过减少血管内皮生长因子诱导的血管生成间接影响 ALK1 信号,从而影响肿瘤生长。